Immunosuppressants that target PD1 and its ligand (PD-L1) can block cancer cell escape and allow immune cells to kill exposed cancer cells.[34] It is thought that patients with EC who carry certain genetic mutations may be potential beneficiaries of immunosuppressants. The gene discussed is CD274; the disease is cancer.